Bivalent drug design is an efficient strategy for increasing potency and selectivity of many drugs. We devised a strategy to prepare agonist-benzodiazepine heterodimers that could simultaneously bind to agonist and BZD sites of the GABAAR. We synthesized a benzodiazepine-MPEG model compound that relied on physiological GABA to elicit flux. We established that a tether at the N1 position of the BZD would not prevent binding to the receptor. However, coupling of GABA amides with long chain PEG tethers studied by another group member resulted in complete loss of agonist activity. We therefore ceased research in this particular area. 1,4-Benzodiazepin-2,5-diones display a wide range of pharmacological activities. Compounds containing the tricyclic proline-derived subtype have received attention as potent anxiolytic agents and as starting materials for anthramycin-inspired anticancer agents. More recently enantiopure (S)-proline-derived 1,4-benzodiazepin-2,5-diones have been recognized as selective α5 GABAA receptor ligands. Despite the impressive diversity of 1,4-benzodiazepine-2,5-diones prepared to date, enantiopure examples possessing a quaternary stereogenic center have been largely unexplored. "Memory of chirality" (MOC) is an emerging strategy for asymmetric synthesis. This technique enables the memory of a sole chiral center in the substrate to be retained in a process that destroys that center. We have used this technique to prepare a library of quaternary proline-derived, thioproline-derived and hydroxyproline-derived 1,4-benzodiazepin-2,5-diones, in high ee. We have developed an efficient synthetic method for preparing oxaproline-derived 1,4-benzodiazepin-2,5-diones in high yields, and by applying the MOC strategy we have prepared quaternary derivatives in acceptable %ee. We envision oxaproline-derived 1,4-benzodiazepin-2,5-diones may exhibit similar or more potent pharmacological properties than proline-derived 1,4-benzodiazepin-2,5-diones. Using density functional theory (DFT) methods, we modeled the formation of an enantiopure, dynamically chiral enolate intermediate and the slow racemization of the enolate on the alkylation reaction time scale. / Ph. D.

La multichimiorésistance est caractérisée par une résistance simultanée à des agents chimiothérapeutiques de structures diverses, induite notamment par l’efflux des substances actives hors des cellules. Les transporteurs ABC (ATP-Binding Cassette) sont des protéines transmembranaires impliquées dans cet efflux et qui participent à l’échec du traitement de certains cancers. Par ailleurs, ce mécanisme d’efflux a également été évoqué dans le cadre de la résistance de certains microorganismes aux antimicrobiens. Dans cette étude, nous avons conçu et synthétisé des dérivés susceptibles d’inhiber certains transporteurs ABC, en particulier, la glycoprotéine-P (Pgp) impliquée dans la multichimiorésistance des tumeurs humaines, et CpABC3, rencontré chez le parasite Cryptosporidium parvum. Dans un premier temps, nous avons synthétisé trois dérivés de type 4-alkyl-imidazo[4,5-b]pyridin-7-one, hétérocycles destinés à se fixer sur le site à ATP des transporteurs ABC. L’activité de ces composés a été évaluée vis-à-vis d’un fragment recombinant (H6-NBD1) de CpABC3, et un de ceux-ci a montré une liaison (faible) à ce fragment. Nous avons ensuite préparé dix-sept dérivés bivalents susceptibles d’inhiber la Pgp, constitués d’une molécule d’adénine (ciblant le site à ATP) reliée à la progestérone (ciblant le site aux stéroïdes) par un bras de géométrie variable. Ces dérivés ont été testés sur des lignées cellulaires K562/R7 surexprimant la Pgp, et un de ceux-ci a montré une activité supérieure à celle de la progestérone. Enfin, nous avons mis au point une synthèse de chaînes de type oligocyclohexylidène, qui sont de bons candidats pour constituer des bras espaceurs rigides / Multi-drug resistance (MDR) is characterized by a simultaneous resistance to a wide range of structurally unrelated chemotherapeutic agents, partly caused by the efflux of active compounds out of the cell. ABC transporters (ATP-Binding Cassette) are transmembrane proteins implicated in this efflux, and thus, they contribute to the failure of some cancer treatments. Furthermore, this mechanism was evoked in some microorganism resistances to antimicrobial agents. In this study, we designed and synthesized potential inhibitors of ABC transporters, especially P-glycoprotein (Pgp) implicated in human tumors multi-drug resistance, and CpABC3, a transporter found in a human parasite, Cryptosporidium parvum. First, we synthesized three 4-alkyl-imidazo[4,5-b]pyridin-7-one derivatives, targeting ATP-binding site of ABC transporters. Their biological activities were evaluated toward a recombinant fragment of the CpABC3 transporter (H6-NBD1 fragment). One of these compounds showed a weak-binding to this fragment. Next, we prepared seventeen progesterone-adenine hybrids as potential bivalent ligands which may bind simultaneously to the ATP-binding site and the steroid-binding region. We chose to synthesize derivatives with rather short-length linkers with different conformational flexibilities. These bivalent compounds were tested on K562/R7 human leukemic cells overexpressing Pgp. One of them has showed a better activity than progesterone. Finally, we optimized the synthesis of oligocyclohexylidene chains, which are good candidates to constitute rigid linkers